American Century Companies Inc. Has $458.21 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

American Century Companies Inc. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 722,467 shares of the biopharmaceutical company’s stock after purchasing an additional 14,921 shares during the quarter. American Century Companies Inc.’s holdings in Regeneron Pharmaceuticals were worth $458,211,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 31 shares during the period. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Tompkins Financial Corp bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $32,000. Finally, Curat Global LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on REGN shares. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 1st. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $890.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Citigroup reaffirmed a “buy” rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Finally, Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a “sector perform” rating in a research report on Monday, August 4th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $838.00.

Regeneron Pharmaceuticals Stock Up 0.8%

Shares of REGN opened at $565.97 on Friday. The stock has a market capitalization of $59.99 billion, a price-to-earnings ratio of 14.26, a price-to-earnings-growth ratio of 1.90 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The business’s 50 day simple moving average is $542.46 and its 200-day simple moving average is $596.26. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned $11.56 EPS. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.